SIGMA-ALDRICH search Sigma-Aldrich AIFM1 products
includes other brands or spellings
|
| block, wb | | Sigma anti-AIF antibody was used in western blot and immunodepletion experiment to study the role of AIF in nuclear phenotype and DNA degradation during apoptosis. |
SANTA CRUZ BIOTECHNOLOGY search Santa Cruz Biotechnology AIFM1 products
includes other brands or spellings
|
| ic | | Santa Cruz Biotechnologies antibody against AIF was used in immunocytochemistry to investigate the oxidant-induced cell death in retinal pigment epithelium cells mediated through the release of apoptosis-inducing factor. |
| wb | | Santa Cruz Biotechnology anti-AIF antibody (E-1) was used in western blot to study the linkage between HDACs, mitochondria, and programmed cell death. |
| wb | | Santa Cruz Biotechnology monoclonal anti-human AIF antibody E-1 was used in western blot to study the involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis which was induced by β-hydroxyisovalerylshikonin. |
| wb | | Santa Cruz Biotechnology mouse monoclonal anti-AIF antibody was used in western blot to study the inhibitory effect of HSP72 on apoptosis-inducing factor (AIF) release in ATP-depleted renal epithelial cells. |
| wb | | Santa Cruz Biotechnology anti-AIF antibody was used in western blot to detect AIF in U937 cells incubated for 24 h with 1-mM SB or 2-µM SAHA ± 100-ng/ml TRAIL in the absence or presence of the pan-caspase inhibitor BOC-D-fmk. |
| wb | | Santa Cruz Biotechnology mouse monoclonal anti-AIF antibody was used in western blot to detect AIF in LAMA84 and LAMA-R cells treated with 1 µM imatinib mesylate. |
| wb | | Santa Cruz Biotechnology anti-AIF antibody was used in human Jurkat cells and in western blot to study the effect of granzyme B on Mcl-1. |
| wb | | Santa Cruz Biotechnology anti-AIF polyclonal antibody was used western blot to demonstrate caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. |
Articles Reviewed |
| 1. Yin Guo et al. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. 2002 |
| 2. Congxiao Zhang et al. Oxidant-induced cell death in retinal pigment epithelium cells mediated through the release of apoptosis-inducing factor. 2003 |
| 3. Kathleen Ruchalski et al. HSP72 inhibits apoptosis-inducing factor release in ATP-depleted renal epithelial cells. 2003 |
| 4. Roberto R Rosato et al. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. 2003 |
| 5. Jie Han et al. Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. 2004 |
| 6. Yun Dai et al. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. 2004 |
| 7. Yutaka Masuda et al. Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. 2004 |
| 8. Robert E Bakin et al. Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis. 2004 |
| 9. Victor J Yuste et al. The contribution of apoptosis-inducing factor, caspase-activated DNase, and inhibitor of caspase-activated DNase to the nuclear phenotype and DNA degradation during apoptosis. 2005 |